221 related articles for article (PubMed ID: 35663965)
1. High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma.
Yu K; Ji Y; Liu M; Shen F; Xiong X; Gu L; Lu T; Ye Y; Feng S; He J
Front Immunol; 2022; 13():881453. PubMed ID: 35663965
[TBL] [Abstract][Full Text] [Related]
2. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase subunit2 (CKS2) promotes malignant phenotypes and epithelial-mesenchymal transition-like process in glioma by activating TGFβ/SMAD signaling.
Feng F; Zhao Z; Cai X; Heng X; Ma X
Cancer Med; 2023 Mar; 12(5):5889-5907. PubMed ID: 36284444
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
5. Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
Yang Z; Cheng H; Zhang Y; Zhou Y
Med Sci Monit; 2021 Mar; 27():e928523. PubMed ID: 33667214
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.
Huang N; Wu Z; Hong H; Wang X; Yang F; Li H
Mol Med Rep; 2019 Jun; 19(6):4761-4769. PubMed ID: 30957190
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma.
Mo C; Wu Y; Ma J; Xie L; Huang Y; Xu Y; Peng H; Chen Z; Zeng M; Mao R
BMC Med Genomics; 2022 Apr; 15(1):81. PubMed ID: 35410253
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I-III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity.
Feng J; Hu M; Li Z; Hu G; Han Y; Zhang Y; Zhang M; Ren J
Cells; 2022 Aug; 11(16):. PubMed ID: 36010686
[TBL] [Abstract][Full Text] [Related]
9. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer.
Chen Q; Fu Y; Liu X; Wang P; Dai S; Zhu F; Liu T; Xu W; Wu J
Mol Carcinog; 2023 Dec; 62(12):1947-1959. PubMed ID: 37642304
[TBL] [Abstract][Full Text] [Related]
11. Decapping enzyme 2 is a novel immune-related biomarker that predicts poor prognosis in glioma.
Mei Y; Lv Q; Tan Z; Zhang Z; Ji Y; Chen S; Shen X
Biotechnol Genet Eng Rev; 2023 May; ():1-22. PubMed ID: 37191010
[TBL] [Abstract][Full Text] [Related]
12. CKS2 modulates cell-cycle progression of tongue squamous cell carcinoma cells partly via modulating the cellular distribution of DUTPase.
Gao F; Li C; Zhao X; Xie J; Fang G; Li Y
J Oral Pathol Med; 2021 Feb; 50(2):175-182. PubMed ID: 33107644
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.
Zhang Y; Li Z; Huang Y; Zou B; Xu Y
BMJ Open; 2024 Jan; 14(1):e073887. PubMed ID: 38296306
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer.
Jonsson M; Fjeldbo CS; Holm R; Stokke T; Kristensen GB; Lyng H
Neoplasia; 2019 Apr; 21(4):353-362. PubMed ID: 30856376
[TBL] [Abstract][Full Text] [Related]
16. CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study based on Bioinformatics and Experiments.
Wang Z; Zhang M; Wu Y; Yu Y; Zheng Q; Li J
J Cancer; 2021; 12(23):6964-6978. PubMed ID: 34729099
[No Abstract] [Full Text] [Related]
17. CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.
Wan Z; Wang L; Yang D; Li P; Liu Q; Wang B
Pathobiology; 2022; 89(1):13-22. PubMed ID: 34333494
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Kita Y; Nishizono Y; Okumura H; Uchikado Y; Sasaki K; Matsumoto M; Setoyama T; Tanoue K; Omoto I; Mori S; Owaki T; Ishigami S; Nakagawa H; Tanaka F; Mimori K; Mori M; Natsugoe S
Oncol Rep; 2014 May; 31(5):1986-92. PubMed ID: 24604089
[TBL] [Abstract][Full Text] [Related]
19. miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma.
Lv M; Zhang X; Li M; Chen Q; Ye M; Liang W; Ding L; Cai H; Fu D; Lv Z
PLoS One; 2013; 8(7):e67591. PubMed ID: 23861775
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma.
Wang JJ; Fang ZX; Ye HM; You P; Cai MJ; Duan HB; Wang F; Zhang ZY
Dis Esophagus; 2013; 26(7):729-36. PubMed ID: 23301842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
